Literature DB >> 16569851

Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.

Didier Hocquet1, Patrice Nordmann, Farid El Garch, Ludovic Cabanne, Patrick Plésiat.   

Abstract

Cefepime (FEP) and ceftazidime (CAZ) are potent beta-lactam antibiotics with similar MICs (1 to 2 mug/ml) for wild-type strains of Pseudomonas aeruginosa. However, recent epidemiological studies have highlighted the occurrence of isolates more resistant to FEP than to CAZ (FEPr/CAZs profile). We thus investigated the mechanisms conferring such a phenotype in 38 clonally unrelated strains collected in two French teaching hospitals. Most of the bacteria (n=32; 84%) appeared to stably overexpress the mexY gene, which codes for the RND transporter of the multidrug efflux system MexXY-OprM. MexXY up-regulation was the sole FEP resistance mechanism identified (n=12) or was associated with increased levels of pump MexAB-OprM (n=5) or MexJK (n=2), synthesis of secondary beta-lactamase PSE-1 (n=10), derepression of cephalosporinase AmpC (n=1), coexpression of both OXA-35 and MexJK (n=1), or production of both PSE-1 and MexAB-OprM (n=1). Down-regulation of the mexXY operon in seven selected strains by the plasmid-borne repressor gene mexZ decreased FEP resistance from two- to eightfold, thereby demonstrating the significant contribution of MexXY-OprM to the FEPr/CAZs phenotype. The six isolates of this series that exhibited wild-type levels of the mexY gene were found to produce beta-lactamase PSE-1 (n=1), OXA-35 (n=4), or both PSE-1 and OXA-35 (n=1). Altogether, these data provide evidence that MexXY-OprM plays a major role in the development of FEP resistance among clinical strains of P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16569851      PMCID: PMC1426951          DOI: 10.1128/AAC.50.4.1347-1351.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance.

Authors:  A Lee; W Mao; M S Warren; A Mistry; K Hoshino; R Okumura; H Ishida; O Lomovskaya
Journal:  J Bacteriol       Date:  2000-06       Impact factor: 3.490

2.  Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa.

Authors:  T Köhler; M Michéa-Hamzehpour; U Henze; N Gotoh; L K Curty; J C Pechère
Journal:  Mol Microbiol       Date:  1997-01       Impact factor: 3.501

3.  Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis.

Authors:  E Mahenthiralingam; M E Campbell; J Foster; J S Lam; D P Speert
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

4.  Evaluation of the Sirscan automated zone reader in a clinical microbiology laboratory.

Authors:  A A Medeiros; J Crellin
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

5.  In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams.

Authors:  G Bonfiglio; F Marchetti
Journal:  Chemotherapy       Date:  2000 Jul-Aug       Impact factor: 2.544

6.  Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides.

Authors:  J R Aires; T Köhler; H Nikaido; P Plésiat
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

7.  Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa.

Authors:  K Poole; N Gotoh; H Tsujimoto; Q Zhao; A Wada; T Yamasaki; S Neshat; J Yamagishi; X Z Li; T Nishino
Journal:  Mol Microbiol       Date:  1996-08       Impact factor: 3.501

8.  The use of analytical isoelectric focusing for detection and identification of beta-lactamases.

Authors:  A Mathew; A M Harris; M J Marshall; G W Ross
Journal:  J Gen Microbiol       Date:  1975-05

9.  OprK and OprM define two genetically distinct multidrug efflux systems in Pseudomonas aeruginosa.

Authors:  M M Hamzehpour; J C Pechere; P Plesiat; T Köhler
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

10.  Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae.

Authors:  A Muller; J M Lopez-Lozano; X Bertrand; D Talon
Journal:  J Antimicrob Chemother       Date:  2004-05-18       Impact factor: 5.790

View more
  54 in total

1.  MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin.

Authors:  Didier Hocquet; Micheline Roussel-Delvallez; Jean-Didier Cavallo; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.

Authors:  Didier Hocquet; Arno Muller; Karine Blanc; Patrick Plésiat; Daniel Talon; Dominique Louis Monnet; Xavier Bertrand
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

Review 3.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

4.  Strain-tailored double-disk synergy test detects extended-spectrum oxacillinases in Pseudomonas aeruginosa.

Authors:  Didier Hocquet; Barbara Dehecq; Xavier Bertrand; Patrick Plésiat
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

Review 5.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

6.  Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.

Authors:  Gabriel Cabot; Carla López-Causapé; Alain A Ocampo-Sosa; Lea M Sommer; María Ángeles Domínguez; Laura Zamorano; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Patrick Plesiat; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

7.  Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation.

Authors:  B Henrichfreise; I Wiegand; W Pfister; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

8.  Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.

Authors:  V Plasencia; N Borrell; M D Maciá; B Moya; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

9.  Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

Authors:  Bartolome Moya; Laura Zamorano; Carlos Juan; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 10.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.